The Effects of NN414, a SUR1/Kir6.2 Selective Potassium Channel Opener in Subjects with Type 2 Diabetes

 

 Buy Article Permissions and Reprints

Abstract

Reducing the workload of the beta cell by inhibiting insulin secretion may provide beneficial effects for patients with type 2 diabetes. The aim of this study was to investigate the effect of NN414, a beta cell selective potassium channel opener in patients with type 2 diabetes. 24 patients were treated for seven days (placebo, 1.5, 4.5, and 10 mg/kg). In accordance with the pharmacological profile a significant and selective inhibition of insulin secretion was observed (1 h post dose). There were no statistically significant effects on overall glycaemic control. Based on OGTT derived parameters a borderline significant improvement in beta-cell function (1st and 2nd phase insulin secretion) was observed from Day 1 to Day 7.

References

• 1 Leahy JL. Impaired β-cell function with chronic hyperglycemia: “overworked β-cell hypothesis”.  Diabetes Rev. 1996;  4 298-319
  PubMedGoogle Scholar
• 2 Carr RD, Brand CL, Bödvarsdottir TB, Hansen JB, Sturis J. NN414, a SUR1/Kir6.2 selective potassium channel opener, reduces blood glucose and improves glucose tolerance in zucker obese rats.  Diabetes. 2003;  52 2513-2518
  CrossrefPubMedGoogle Scholar
• 3 Zdravkovic M, Kruse M, Rost KL, Moss J, Kecskes A, Dyrberg T. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener, in healthy male subjects.  J Clin Pharmacol. 2005;  45 763-772
  PubMedGoogle Scholar
• 4 Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Haeften T Van, Haring H, Fritsche A, Gerich J. Assessment of insulin secretion from the oral glucose tolerance test in white patients with type 2 diabetes.  Diabetes Care. 2000;  23 1440-1441
  PubMedGoogle Scholar

Correspondence

M. ZdravkovicMD, PhD 

Novo Nordisk A/S

Krogshøjsvej 55A

DK-2880 Bagsværd

Denmark

Phone: +45/44/42 16 16

Fax: +45/44/43 67 40

Email: mzd@novonordisk.com